SCHEMBL26447922

SCHEMBL26447922

CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4ccc5nc(NC6CCCC6)sc5c4)n3)nc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ DYRK2 Q92630 15/20 1.00
▸ CDK6 Q00534 5/20 0.73
▸ CCND1 P24385 4/20 0.73
▸ CDK4 P11802 3/20 0.73
▸ CCND3 P30281 2/20 0.73
▸ CCNT1 O60563 1/20 0.73
▸ CCNA2 P20248 1/20 0.73
▸ CDK2 P24941 1/20 0.73
▸ CDK7 P50613 1/20 0.73
▸ CDK9 P50750 1/20 0.73
▸ CCNH P51946 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30679279 1.00 DYRK2 (1.00) DYRK2CDK6CCND1CDK4CCND3
SCHEMBL30679269 0.92 DYRK2 (1.00) DYRK2CDK6CCND1CDK4CCND3
SCHEMBL26447943 0.92 DYRK2 (1.00) DYRK2CDK6CCND1CDK4CCND3
SCHEMBL26447925 0.91 DYRK2 (0.98) DYRK2CDK6CCND1CDK4CCND3
SCHEMBL26680023 0.91 DYRK2 (1.00) DYRK2CDK6CCND1CDK4CCND3
SCHEMBL30679268 0.91 DYRK2 (1.00) DYRK2CDK6CCND1CDK4CCND3
Hydrochloric Acid SCHEMBL26680002 0.90 DYRK2 (1.00) DYRK2CDK6CCND1CDK4CCND3
Hydrochloric Acid SCHEMBL30569712 0.90 DYRK2 (1.00) DYRK2CDK6CCND1CDK4CCND3
SCHEMBL32677357 0.90 DYRK2 (0.82) DYRK2CDK6CCND1CDK4CCND3
SCHEMBL26447930 0.90 DYRK2 (0.82) DYRK2CDK6CCND1CDK4CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4282864-B1 CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD (CN) 2025-08-13 — — EP disclosed
EP-4282864-A1 CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) 2023-11-29 — — EP disclosed
EP-4282864-A1 CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) 2023-11-29 — — EP disclosed
US-20230303553-A1 CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) 2023-09-28 — — US disclosed
CN-112390793-B CDK6/DYRK2 double-target inhibitor and preparation method and application thereof 中国药科大学 2021-04-27 — — CN disclosed
CN-112390793-A CDK6/DYRK2 double-target inhibitor and preparation method and application thereof 中国药科大学 2021-02-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303553-A1 CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF CDK6, DYRK2, CDK16 DYRK2 2/4885CDK6 1/4885CCND1 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback